Repligen Corporation Investor Presentation — June 2017

Document content

Repligen and Spectrum to Join Forces

Tony J. Hunt, President and CEO

June 23, 2017 Jon K. Snodgres, CFO 2 Safe Harbor

This presentation contains forward looking statements which are made pursuant to the safe harbor provisions

of Section 27A of the Securities Act of 1933 , as amended, and Section 21E of the Securities Exchange Act of

1934 , as amended . These statements are subject to risks and uncertainties which may cause our plans to

change or actual results to differ materially from those anticipated . In particular, unforeseen events outside of

our control may adversely impact future results . Additional information concerning these factors is discussed

in our reports filed with the Securities and Exchange Commission including recent Form 8-Ks, our most recent

Annual Report on Form 10K and our most recent Quarterly report on Form 10Q. The forward looking

statements in this presentation reflect management’s current views and may become obsolete as a result of

new information, future events or otherwise . We may not update such forward looking statements to reflect a

change of events or circumstances that occur after the date hereof, except as required by law. The industry and

market data contained in this presentation are based on management’s own estimates, independent

publications, government publications, reports by market research firms or other published independent

sources, and, in each case, are believed by management to be reasonable estimates . Although we believe

these sources are reliable, we have not independently verified the information .

profitability step -up •Adds leading player in bioprocess filtration; single -use cartridge and systems

•Spectrum pioneered the development of disposable hollow fiber (HF) tangential flow

filtration (TF) cartridges widely used in bioprocess applications

•Significantly increases addressable market

•Addressable market increases by up to $500M, from $900M -$1B to $ 1.4B -$1.5B

•Strong product fit that fills XCell™ ATF gap with consumable filtration portfolio

•Broadens our R&D engine to drive next -generation filtration products

•Expands our end markets beyond mAb manufacturing into vaccines, recombinant

proteins, gene therapy production

•Expected to more than double our direct sales organization, adds direct presence

•Consistent with our targeted M&A strategy…

Technology leadership in bioprocessing